FY2019 Earnings Forecast for Applied Genetic Technologies Corporation (AGTC) Issued By Cantor Fitzgerald

Applied Genetic Technologies Corporation (NASDAQ:AGTC) – Investment analysts at Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Applied Genetic Technologies in a report released on Monday. Cantor Fitzgerald analyst M. Goldstein expects that the biotechnology company will earn ($2.51) per share for the year. Cantor Fitzgerald has a “Hold” rating and a $9.00 price objective on the stock.

Several other brokerages have also recently weighed in on AGTC. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (down from $16.00) on shares of Applied Genetic Technologies in a report on Thursday, September 14th. BMO Capital Markets reiterated an “outperform” rating and issued a $7.00 target price (down from $14.00) on shares of Applied Genetic Technologies in a report on Thursday, September 14th. Stifel Nicolaus lowered their target price on Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, September 14th. ValuEngine cut Applied Genetic Technologies from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Finally, Zacks Investment Research cut Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 31st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.17.

Shares of Applied Genetic Technologies (NASDAQ AGTC) opened at $4.30 on Thursday. Applied Genetic Technologies has a 1-year low of $3.25 and a 1-year high of $10.15.

Several hedge funds have recently modified their holdings of the business. Credit Suisse AG raised its position in shares of Applied Genetic Technologies by 10.9% in the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after acquiring an additional 2,662 shares in the last quarter. DAFNA Capital Management LLC raised its position in shares of Applied Genetic Technologies by 2.4% in the 2nd quarter. DAFNA Capital Management LLC now owns 421,000 shares of the biotechnology company’s stock worth $2,147,000 after acquiring an additional 10,000 shares in the last quarter. ClariVest Asset Management LLC raised its position in shares of Applied Genetic Technologies by 18.5% in the 3rd quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock worth $391,000 after acquiring an additional 15,491 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Applied Genetic Technologies by 10.6% in the 1st quarter. Geode Capital Management LLC now owns 161,831 shares of the biotechnology company’s stock worth $1,116,000 after acquiring an additional 15,575 shares in the last quarter. Finally, Nine Chapters Capital Management LLC bought a new position in shares of Applied Genetic Technologies in the 3rd quarter worth $113,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.com-unik.info/2018/01/06/fy2019-earnings-forecast-for-applied-genetic-technologies-corporation-agtc-issued-by-cantor-fitzgerald.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Earnings History and Estimates for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit